Bone Biomechanics and Bone Quality: Effects of Pharmaceutical Agents Used to Treat Osteoporosis

David Burr

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The biomechanical properties of bone define skeletal fragility. Surrogates such as bone density or biochemical markers are used to estimate the mechanical properties of bone because mechanical properties cannot be measured in a clinical environment. Within the set of bone’s mechanical properties, the material properties of the tissue itself are the defining feature of bone quality. Because they are the summation of all bone quality characteristics, bone’s material properties can define whether bone is fragile or healthy, even though other studies are required to determine the exact characteristics of microarchitecture, microdamage, and tissue physical properties that make the bone more or less fragile. For these reasons, measurement of the mechanical properties of bone is critical to assess bone health following drug treatments meant to ameliorate low bone mass, and are a common outcome measure in preclinical studies that assess the potential of these medications. This review describes the effects of existing anti-catabolic (bisphosphonates, SERMS, RANKL inhibitors) and anabolic (rhPTH (1-34) agents used to treat osteoporosis, and also several emerging potential therapies (cathepsin K inhibitors, anti-sclerostin antibody), on bone’s structural and material mechanical properties.

Original languageEnglish (US)
Pages (from-to)1-21
Number of pages21
JournalClinical Reviews in Bone and Mineral Metabolism
DOIs
StateAccepted/In press - Jul 26 2016

Fingerprint

Biomechanical Phenomena
Osteoporosis
Bone and Bones
Pharmaceutical Preparations
Cathepsin K
Diphosphonates
Bone Density
Anti-Idiotypic Antibodies
Biomarkers
Outcome Assessment (Health Care)

Keywords

  • Biomechanics
  • Bisphosphonates
  • Fragility
  • Osteoporosis
  • Quality

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

@article{7c85845e296b49678cf0b405447b09ba,
title = "Bone Biomechanics and Bone Quality: Effects of Pharmaceutical Agents Used to Treat Osteoporosis",
abstract = "The biomechanical properties of bone define skeletal fragility. Surrogates such as bone density or biochemical markers are used to estimate the mechanical properties of bone because mechanical properties cannot be measured in a clinical environment. Within the set of bone’s mechanical properties, the material properties of the tissue itself are the defining feature of bone quality. Because they are the summation of all bone quality characteristics, bone’s material properties can define whether bone is fragile or healthy, even though other studies are required to determine the exact characteristics of microarchitecture, microdamage, and tissue physical properties that make the bone more or less fragile. For these reasons, measurement of the mechanical properties of bone is critical to assess bone health following drug treatments meant to ameliorate low bone mass, and are a common outcome measure in preclinical studies that assess the potential of these medications. This review describes the effects of existing anti-catabolic (bisphosphonates, SERMS, RANKL inhibitors) and anabolic (rhPTH (1-34) agents used to treat osteoporosis, and also several emerging potential therapies (cathepsin K inhibitors, anti-sclerostin antibody), on bone’s structural and material mechanical properties.",
keywords = "Biomechanics, Bisphosphonates, Fragility, Osteoporosis, Quality",
author = "David Burr",
year = "2016",
month = "7",
day = "26",
doi = "10.1007/s12018-016-9217-1",
language = "English (US)",
pages = "1--21",
journal = "Clinical Reviews in Bone and Mineral Metabolism",
issn = "1534-8644",
publisher = "Humana Press",

}

TY - JOUR

T1 - Bone Biomechanics and Bone Quality

T2 - Effects of Pharmaceutical Agents Used to Treat Osteoporosis

AU - Burr, David

PY - 2016/7/26

Y1 - 2016/7/26

N2 - The biomechanical properties of bone define skeletal fragility. Surrogates such as bone density or biochemical markers are used to estimate the mechanical properties of bone because mechanical properties cannot be measured in a clinical environment. Within the set of bone’s mechanical properties, the material properties of the tissue itself are the defining feature of bone quality. Because they are the summation of all bone quality characteristics, bone’s material properties can define whether bone is fragile or healthy, even though other studies are required to determine the exact characteristics of microarchitecture, microdamage, and tissue physical properties that make the bone more or less fragile. For these reasons, measurement of the mechanical properties of bone is critical to assess bone health following drug treatments meant to ameliorate low bone mass, and are a common outcome measure in preclinical studies that assess the potential of these medications. This review describes the effects of existing anti-catabolic (bisphosphonates, SERMS, RANKL inhibitors) and anabolic (rhPTH (1-34) agents used to treat osteoporosis, and also several emerging potential therapies (cathepsin K inhibitors, anti-sclerostin antibody), on bone’s structural and material mechanical properties.

AB - The biomechanical properties of bone define skeletal fragility. Surrogates such as bone density or biochemical markers are used to estimate the mechanical properties of bone because mechanical properties cannot be measured in a clinical environment. Within the set of bone’s mechanical properties, the material properties of the tissue itself are the defining feature of bone quality. Because they are the summation of all bone quality characteristics, bone’s material properties can define whether bone is fragile or healthy, even though other studies are required to determine the exact characteristics of microarchitecture, microdamage, and tissue physical properties that make the bone more or less fragile. For these reasons, measurement of the mechanical properties of bone is critical to assess bone health following drug treatments meant to ameliorate low bone mass, and are a common outcome measure in preclinical studies that assess the potential of these medications. This review describes the effects of existing anti-catabolic (bisphosphonates, SERMS, RANKL inhibitors) and anabolic (rhPTH (1-34) agents used to treat osteoporosis, and also several emerging potential therapies (cathepsin K inhibitors, anti-sclerostin antibody), on bone’s structural and material mechanical properties.

KW - Biomechanics

KW - Bisphosphonates

KW - Fragility

KW - Osteoporosis

KW - Quality

UR - http://www.scopus.com/inward/record.url?scp=84979708084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979708084&partnerID=8YFLogxK

U2 - 10.1007/s12018-016-9217-1

DO - 10.1007/s12018-016-9217-1

M3 - Article

AN - SCOPUS:84979708084

SP - 1

EP - 21

JO - Clinical Reviews in Bone and Mineral Metabolism

JF - Clinical Reviews in Bone and Mineral Metabolism

SN - 1534-8644

ER -